Immunophenotypic characteristics of multipotent mesenchymal stromal cells that affect the efficacy of their use in the prevention of acute graft vs host disease

Table 2 Changes in the mean fluorescence intensity of surface multipotent mesenchymal stromal cells untreated and treated with interleukin 1β, interferon gamma and tumour necrosis factor alpha antigens

MFI
	MSCs		MSCs treated with IL1β		MSCs treated with IFN		MSCs treated with TNF
Antigen	Effective	Ineffective	Effective	Ineffective	Effective	Ineffective	Effective	Ineffective
HLA-ABC	14561 ± 7741	8767 ± 1434	14740 ± 10211	8850 ± 994	15200 ± 9601	10208 ± 1189	21174 ± 1615	15706 ± 2938
HLA-DR	752 ± 1501	188 ± 42	610 ± 1541	149 ± 25	1077 ± 1531	423 ± 163	659 ± 1371	169 ± 38
CD54	4881 ± 371	4447 ± 1203	13773 ± 32181	4234 ± 1612	7889 ± 8161	4378 ± 1566	61708 ± 5998	65461 ± 11324
CD73	3047 ± 253	2354 ± 343	3396 ± 305	2226 ± 543	3414 ± 383	2678 ± 655	3395 ± 305	3370 ± 605
CD90	57679 ± 2626	49241 ± 7022	60117 ± 3990	45739 ± 9525	56500 ± 30721	40335 ± 4502	55799 ± 3471	45198 ± 7142
CD105	35682 ± 26231	21471 ± 3247	34402 ± 2490	29665 ± 6032	41171 ± 3118	30525 ± 5609	30431 ± 2471	24260 ± 3466
CD146	4345 ± 5341	1807 ± 482	3546 ± 497	3124 ± 688	3762 ± 479	2378 ± 707	3137 ± 387	3463 ± 539
CD274	293 ± 37		261 ± 38	227 ± 204	400 ± 104	304 ± 219	341 ± 54	322 ± 81
%CD54	56 ± 3	50 ± 9	57 ± 4	42 ± 8	66 ± 3	55 ± 8	89 ± 2	93 ± 4

¹Significant differences between effective and ineffective samples. MFI: Mean fluorescence intensity; MSC: Multipotent mesenchymal stromal cell; IL1β: Interleukin 1β; IFN: Interferon gamma; TNF: Tumour necrosis factor alpha.